PolyPid

Company Overview

Snapshot

Founded in February 2008, PolyPid operates with 51–200 employees and has raised a total of $239.24 million across 15 funding rounds. The company went public on NASDAQ in June 2020, a significant milestone in its journey.

Business overview

PolyPid is a late-stage biopharmaceutical company dedicated to enhancing surgical outcomes through its proprietary Polymer-Lipid Encapsulation matriX (PLEX) technology. This innovative platform enables the precise, controlled, and prolonged release of therapeutics, delivering active pharmaceutical ingredients over durations ranging from days to months. The company's lead product candidate, D-PLEX100, is currently in Phase 3 clinical trials for the prevention of abdominal colorectal surgical site infections. Additionally, PolyPid is advancing OncoPLEX, a preclinical-stage program focused on treating solid tumors, starting with glioblastomas. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drug Delivery, serving the broader healthcare and life sciences markets.

Strategic signal

In October 2024, PolyPid announced the publication of its Phase 3 SHIELD I trial results for D-PLEX₁₀₀ in the International Journal of Surgery, highlighting its potential in preventing surgical site infections in abdominal colorectal surgery. This publication provides crucial clinical validation for its lead product candidate, reinforcing the company's scientific credibility and advancing its regulatory pathway for D-PLEX₁₀₀.

Company Intelligence Q&A

When did PolyPid go public?

PolyPid went public on NASDAQ in June 2020.

What is the latest clinical development for D-PLEX₁₀₀?

In October 2024, PolyPid announced the publication of its Phase 3 SHIELD I trial results for D-PLEX₁₀₀ in the International Journal of Surgery, highlighting its efficacy in preventing surgical site infections in abdominal colorectal surgery.

What was a recent financing event for PolyPid?

In January 2024, PolyPid announced a private placement for $16 million in gross proceeds, with participation from Rosalind Advisors.

What is PolyPid's PLEX technology?

PolyPid's PLEX (Polymer-Lipid Encapsulation matriX) technology is a proprietary platform that pairs with active pharmaceutical ingredients to enable the precise delivery of drugs at optimal release rates over durations ranging from days to months, aiming to improve surgical outcomes.

What is the status of PolyPid's OncoPLEX program?

PolyPid's OncoPLEX is currently in preclinical stage testing for the treatment of solid tumors, beginning with glioblastomas.